



Docket No: AM100341
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: SCHMITT, Mark R. et al.
Application No.: 09/895,975 Group Art No.: 1624
Filed: June 29, 2001 Examiner: Tamthon Ngo Truong
For: SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER
AGENTS
Confirmation No.: 9267
Customer Number: 25291

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ER672185107 US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

May 16, 2005
Date

Daniel B. Moran
Daniel B. Moran

05/18/2005 SMINASS1 00000046 011425 09895975
01 FC:1806 180.00 DA

2. Identification of Time of Filing

This Information Disclosure Statement

- a. is filed within three months of the filing date of the application.
- b. is filed before the mailing date of a first Office Action on the merits.
- c. is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. Certification under 37 CFR 1.97(e) and 1.704(d)

The undersigned attorney certifies

- a. that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

Newly Cited Information

A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Application Number , filed on of for

Concise Explanation
Documents cited above which are not in the English Language
a. have been explained in the specification.
b. have an abstract (or other concise explanation) in English enclosed or if
readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

Fees
 Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:

Charge Deposit Account No. 01-1425 in the amount of \$180.00

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:

Credit any overpayment and charge any underpayment to Deposit Account No.
01-1425.



Daniel B. Moran
Daniel B. Moran

Agent for Applicants
Reg. No. 41,204

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-2224



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

MAY 16 2005

PATENT & TRADEMARK OFFICE

of

1

Complete if Known	
Application Number	09/895,975
Filing Date	June 29, 2001
First Named Inventor	SCHMITT, Mark R. et al.
Group Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	AM100341

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
1.						

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
2.								<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
		3.	4.	
		H.P. Hsieh et al, Bioorganic and Chemistry Letters, 13, 101-105 (2003);		<input type="checkbox"/>
		Park et al, International Journal of Oncology, 20(2), 333-338 (2002);		<input type="checkbox"/>
		Gerald Bacher et al, Cancer Research, 61, 392-399, January 1, 2001		<input type="checkbox"/>
		M. Iwahana et al, Anticancer research 20(2A), 785-92 (2000 Mar-Apr).		<input type="checkbox"/>
		Richard J. Bleicher et al, Cancer Letters, 150, 129-135 (2000);		<input type="checkbox"/>
		Qian Cheng, et al, Bioorganic and Medicinal Chemistry Letters, 10, 517-521, (2000);		<input type="checkbox"/>
		Ke. Chen et al, J.Med.Chem. 1997, 40, 3049-3056 ;		<input type="checkbox"/>
	10.	(Trock B. J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. (Bethesda), 89: 917-931, 1997)		<input type="checkbox"/>
	11.	N. Koyanagi et al, Cancer Research, 54(7), 1702-6 (1994 April 1		<input type="checkbox"/>

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.